10-QPharmaceutical Preparations

Merck & Co., Inc.

MRK · Period ending 2026-03-31 · Filed 2026-05-04

Valuation

Pharmaceutical Preparations
Live · Yahoo Finance

Price

$114.90

52-Week Range

$76.66$114.90 now$125.14

Decision Context

Scores are balanced across the six engines. No single dimension dominates — this is consistent with a stable, mid-tier quality business.

Based on filing period ending Mar 2026

FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.

MRK vs

Macro Context

SWOT Analysis — MRK

Inflationary Boom

Strengths

  • Total Assets: $136.9B (+16.9% YoY) — Total assets grew 17% — the company's resource base expanded.

  • EPS (Diluted): $7.28 (+8.0% YoY) — Earnings per share rose 8% — each share earned more.

  • Net Income: $18.3B (+6.6% YoY) — Profit grew 7% — the company kept more of each dollar earned.

Weaknesses

  • Operating Cash Flow: $16.5B (-23.3% YoY) — Operating cash flow fell 23% but remained positive.

Opportunities

  • Revenue: $65.0B (+1.3% YoY) — Revenue grew 1% — the company sold more goods or services than the prior year.

Threats

No significant threats flagged.

Financial Charts

Revenue vs Net Income

Margin Trend

Operating Cash Flow

Year-over-Year Changes

Operating Cash Flow

$16.5B

was $21.5B

−23.3%

Operating cash flow fell 23% but remained positive.

Total Assets

$136.9B

was $117.1B

+16.9%

Total assets grew 17% — the company's resource base expanded.

EPS (Diluted)

$7.28

was $6.74

+8.0%

Earnings per share rose 8% — each share earned more.

Net Income

$18.3B

was $17.1B

+6.6%

Profit grew 7% — the company kept more of each dollar earned.

Revenue

$65.0B

was $64.2B

+1.3%

Revenue grew 1% — the company sold more goods or services than the prior year.

Price History

Technical Signals

Daily closes · 1-year data

Latest News

via Finnhub

Filing History — MRK

Get the weekly digest

5 company reports + macro context every week, free. No spam.

  • Unlimited goal simulations
  • 5 free company report summaries per day
  • Weekly financial insights newsletter

External Links

Trade MRK

Links open broker research pages. Not an endorsement or recommendation.

Research Merck & Co., Inc.

Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.